TScan Therapeutics, Inc. (NASDAQ:TCRX) to Post Q1 2023 Earnings of ($0.80) Per Share, HC Wainwright Forecasts

TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) – Investment analysts at HC Wainwright dropped their Q1 2023 earnings per share estimates for TScan Therapeutics in a research report issued to clients and investors on Thursday, March 9th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.80) for the quarter, down from their prior forecast of ($0.71). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q2 2023 earnings at ($0.82) EPS, Q3 2023 earnings at ($0.84) EPS, Q4 2023 earnings at ($0.86) EPS, FY2023 earnings at ($3.32) EPS, FY2024 earnings at ($2.96) EPS, FY2025 earnings at ($2.84) EPS, FY2026 earnings at ($2.73) EPS and FY2027 earnings at ($2.22) EPS.

TScan Therapeutics Stock Down 3.0 %

TScan Therapeutics stock opened at $2.93 on Monday. The stock’s fifty day moving average is $2.32 and its two-hundred day moving average is $2.51. The company has a debt-to-equity ratio of 0.29, a current ratio of 7.17 and a quick ratio of 8.51. TScan Therapeutics has a 1-year low of $1.45 and a 1-year high of $4.56. The stock has a market cap of $70.55 million, a PE ratio of -1.07 and a beta of 0.44.

Institutional Trading of TScan Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in shares of TScan Therapeutics during the fourth quarter worth about $31,000. Alphabet Inc. acquired a new stake in shares of TScan Therapeutics during the third quarter worth about $3,285,000. Vanguard Group Inc. increased its position in shares of TScan Therapeutics by 13.9% during the third quarter. Vanguard Group Inc. now owns 257,416 shares of the company’s stock worth $785,000 after purchasing an additional 31,352 shares in the last quarter. Prudential Financial Inc. acquired a new stake in shares of TScan Therapeutics during the third quarter worth about $34,000. Finally, Privium Fund Management UK Ltd acquired a new stake in shares of TScan Therapeutics during the third quarter worth about $48,000. Institutional investors and hedge funds own 48.21% of the company’s stock.

TScan Therapeutics Company Profile

(Get Rating)

TScan Therapeutics, Inc, a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.